The diagnosis and management of pre-invasive breast disease: Problems associated with management of pre-invasive lesions by Purushotham, Anand D
309 BCS = breast-conserving surgery; DCIS = ductal carcinoma in situ.
Available online http://breast-cancer-research.com/content/5/6/309
Surgical management of ductal carcinoma in
situ (DCIS)
The primary treatment of DCIS is based on the extent of
DCIS in the breast.
Widespread DCIS (Fig.1) is treated by mastectomy with
excision of the nipple areola complex with or without
immediate or delayed reconstruction using prosthetic or
autogenous tissue techniques. Where immediate breast
reconstruction is performed, a skin-sparing mastectomy is
preferred. Mastectomy results in the removal of most of
the breast tissue with a low local recurrence rate and
excellent survival.
Localised DCIS is treated by wire-guided localisation and
wide local excision followed by adjuvant therapy if appro-
priate. Surgical excision should ideally follow the segmen-
tal anatomy of the breast, and it is crucial to ensure an
‘adequate’ radial excision margin. Intra-operatively, in the
presence of microcalcification, a specimen radiograph of
the excised tissue, with appropriate orientation of the
specimen, will provide an initial guide to adequacy of exci-
sion (Fig.2). It is important to place marker sutures and
metallic clips to orientate the specimen accurately. If the
specimen X-ray demonstrates the presence of microcalci-
fication close to one or more radial margins, further exci-
sion of the margin(s) in question can be performed
immediately. In many cases this will obviate the need for a
second procedure.
Local protocols agreed by the multidisciplinary team will
ensure accurate interpretation of the results of histopathol-
ogy, thereby facilitating subsequent treatment decisions.
Occasionally the extent of DCIS is underestimated radio-
logically and further surgery may be required on the basis
of the results of histopathology [1]. In some situations, it
may be possible to remove relatively large areas of DCIS
and preserve the breast by performing oncoplastic proce-
dures.
Margin of excision
DCIS is a potentially curable disease. ‘Adequate’ surgical
excision is required, to minimise the risk of local recur-
rence. Data from several studies demonstrate that approxi-
mately half of all local recurrences will be invasive
carcinoma [2–4]. There is currently no consensus on what
constitutes an ‘adequate’ margin of excision. The margin
of excision can be described as ‘involved’ or ‘close’ or
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Abstract
The treatment of ductal carcinoma in situ (DCIS) involves adequate surgical excision with adjuvant
radiotherapy where appropriate. An inadequate excision margin and young age are independent risk
factors for local recurrence. Routine surgery to axillary lymph nodes is not recommended in pure DCIS.
In localised DCIS, adjuvant radiotherapy is recommended on the basis of tumour size, margin width
and pathological subtypes. The role of adjuvant tamoxifen as systemic therapy is controversial. The
treatment of atypical ductal/lobular hyperplasia and lobular carcinoma in situ involves surgical excision
to exclude coexisting DCIS or invasive disease.
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defined in terms of distance in millimetres between dis-
eased and normal breast tissue. The consensus view rec-
ommends a second re-excision where a margin is
involved. Mastectomy may be indicated where there is
extensive DCIS close to several margins, indicating an
initial underestimate of the extent of the disease in the
breast, because the extent of DCIS does not always corre-
spond to the extent of microcalcification. A study examin-
ing the width of excision margin, in patients undergoing
breast-conserving surgery (BCS) with or without radio-
therapy for DCIS, demonstrated a significantly higher local
recurrence rate in patients with a final excision margin of
1mm or less than in those with a margin of more than
1mm [5]. This is hardly surprising given that DCIS, like
invasive carcinoma, does not have a concentric distribu-
tion, and the reason for the reported higher local recur-
rence might be related to a failure to achieve complete
excision of existing disease. Further evidence exists in the
literature for the benefit of achieving a minimum excision
margin of 10mm in patients with DCIS. In a series of 342
patients undergoing BCS with or without radiotherapy for
localised DCIS, an excision margin of 10mm or more with
adjuvant radiotherapy achieved a non-significant reduction
of 8% in local recurrence in the high-grade DCIS group
[6]. However, this excision margin might be excessive
because this does not take into account the fact that
DCIS, like invasive disease, is heterogeneous and cases
of low-grade and intermediate-grade DCIS might not
require this extent of excision, notwithstanding the benefit
of radiotherapy. Despite the lack of clear published evidence
of what constitutes an ‘adequate’ margin of excision, it is
important that individual institutions adopt appropriate local
protocols and evaluate their longer-term results, amending
these protocols as further evidence on adequacy of surgi-
cal excision margins emerges in the literature.
Other factors influencing surgical treatment
Age
Some studies have examined the influence of younger age
on local recurrence and prognosis in patients with DCIS.
Experience from North America and Europe has shown
that younger age is associated with a higher rate of local
recurrence. In a series of 422 patients undergoing BCS
and adjuvant radiotherapy with a mean follow-up of
9.4 years, local recurrence relative to patient age was
31% in patients aged less than 40 years, 13% in the
40–49-year age group, 8% in the 50–59-year age group
and 6% in patients aged more than 60 years. On multivari-
ate analysis, an age of less than 40 years was shown to be
an independent factor for local recurrence [7]. Similar find-
ings were described by the French Cancer Centers in 515
patients undergoing BCS and radiotherapy for DCIS. At a
mean follow-up of 7 years, the local recurrence rate rela-
tive to patient age was 29% in patients less than 40 years
of age, 13% in patients aged 41–60 years and 8% in
patients aged more than 61 years. On multivariate analy-
sis, younger age was found to be an independent prog-
nostic factor for local recurrence [4]. A recent review
Figure 1
Mammogram demonstrating widespread ductal carcinoma in situ.
Figure 2
Specimen radiograph after wide local excision for localised ductal
carcinoma in situ, demonstrating microcalcification in the centre of the
specimen with marker clips for orientation. The additional titanium clip
visible is that inserted after mammotome core biopsy.311
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indicates that younger age is associated with more wide-
spread DCIS, more adverse pathological prognostic
factors, higher local recurrence rate and rate of invasive
recurrence, and worse prognosis [8].
Family history of breast cancer
Two small series of patients treated for DCIS have shown
a higher local recurrence rate in patients with a family
history of breast cancer. These studies require confirma-
tion [9,10].
Despite the above data, it would be premature to recom-
mend more radical surgical treatment for patients with
localised DCIS that can be treated by BCS on the basis of
the extent of the disease within the breast. It might be
more appropriate to recommend adjuvant radiotherapy in
this subgroup of patients to minimise the risk of local
recurrence.
Axillary lymph node surgery
As a general guidance, axillary lymph node clearance is
not required if the disease is pure DCIS with no evidence
of invasion. This might be reserved for patients in whom
subsequent final histopathology demonstrates invasive
disease in the excision specimen. Surgical care needs to
be exercised in patients who have undergone immediate
breast reconstruction, especially if the latissimus dorsi flap
has been used for this purpose.
With the advent of sentinel-node biopsy in breast cancer,
reports have emerged in the literature of its value in DCIS.
Using a combination of conventional serial sectioning,
haematoxylin/eosin staining and immunohistochemistry, a
6–13% rate of positive sentinel nodes was detected in
patients with proven DCIS and no evidence of invasion
[11–13]. The above findings should be interpreted with
caution because the relevance of axillary micrometastasis
in determining prognosis in invasive breast cancer
remains controversial.
Adjuvant radiotherapy
The role of adjuvant radiotherapy after BCS in the man-
agement of DCIS has been examined in randomised trials.
In the NSABP-B17 study, at a mean follow-up of
7.5 years, the benefit of lumpectomy plus radiation was
demonstrated by a reduction in the incidence of ipsilateral
non-invasive breast recurrence from 13.4% to 8.2% and
of ipsilateral invasive breast recurrence from 13.4% to
3.9% [2]. In the EORTC randomised phase III trial 10853,
the benefit of adjuvant radiotherapy was demonstrated by
a reduction in local recurrence from 17% (wide local exci-
sion) to 10% (wide local excision plus radiotherapy) [3].
The results of this trial have been recently debated on the
basis of patient selection for entry into the trial. The
authors suggest that as a result, the findings of this trial
might not be applicable to all patients with DCIS [14].
Until further confirmation of the benefit of radiotherapy in
subgroups of patients with DCIS have been confirmed, a
pragmatic approach might be to apply the Van Nuys Prog-
nostic Index, which relies on tumour size, margin width,
and pathological classification in recommending adjuvant
radiotherapy to selected patients with DCIS [15].
Role of tamoxifen in DCIS
In the NSABP-B24 randomised trial examining the benefit
of adjuvant tamoxifen in women undergoing BCS and
radiotherapy for localised DCIS, patients in the tamoxifen
group had fewer breast-cancer events at 5 years than did
those on placebo (8.2% versus 13.4%) [16]. This benefit
of tamoxifen might be attributed to its chemopreventive
effect as demonstrated in two randomised trials: the P1
and IBIS trials [17,18]. However, this effect was not
demonstrated in two other trials [19,20]. If this finding of
the chemopreventive effect of tamoxifen in women at
increased risk of breast cancer is accepted, then it would
not be unreasonable to consider women with a history of
DCIS for such therapy [21].
Surgical management of core biopsies
showing atypical ductal/lobular hyperplasia
and lobular carcinoma in situ
A preoperative diagnosis on core biopsy of atypical ductal
hyperplasia, atypical lobular hyperplasia or lobular carci-
noma in situ indicates the possibility of a 14–21% inci-
dence of associated DCIS or invasive carcinoma [22–25].
The role of surgery is therefore to rule out this possibility.
Surgical excision is performed by guidewire localisation
with adequate specimen orientation. If further excision
shows the presence of DCIS or invasive carcinoma, this
lesion is treated on its own merits. If further excision
shows no evidence of further disease, a mammography
screening programme can be set up whose frequency is
as yet unclear. Current surgical consensus does not advo-
cate mastectomy in the management of these patients.
However, in the presence of a strong family history of
breast cancer, prophylactic mastectomy may be dis-
cussed on the basis of the merits of the family history and
the patient supported in her decision. In view of the results
of the P1 and IBIS studies, it might be worth also consid-
ering the option of chemoprevention with tamoxifen in this
group of patients [17,18].
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